侧移黏膜瓣术治疗复杂性肛瘘的临床研究

注册号:

Registration number:

ChiCTR2400087316 

最近更新日期:

Date of Last Refreshed on:

2024-07-24 18:37:38 

注册时间:

Date of Registration:

2024-07-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

侧移黏膜瓣术治疗复杂性肛瘘的临床研究

Public title:

Clinical study on the treatment of complex anal fistula with lateral mucosal flap surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

侧移黏膜瓣术治疗复杂性肛瘘的临床研究

Scientific title:

Clinical study on the treatment of complex anal fistula with lateral mucosal flap surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王浩 

研究负责人:

王浩 

Applicant:

Hao Wang 

Study leader:

Hao Wang 

申请注册联系人电话:

Applicant telephone:

+86 159 5489 9305

研究负责人电话:

Study leader's
telephone:

+86 138 5165 6633

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

cnzhwh@126.com

研究负责人电子邮件:

Study leader's E-mail:

cnzhwh@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市秦淮区汉中路155号

研究负责人通讯地址:

江苏省南京市秦淮区汉中路155号

Applicant address:

155 Hanzhong Road, Qinhuai District, Nanjing, Jiangsu

Study leader's address:

155 Hanzhong Road, Qinhuai District, Nanjing, Jiangsu

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南京中医药大学附属医院(江苏省中医院)

Applicant's institution:

Nanjing University of Traditional Chinese Medicine Affiliated Hospital (Jiangsu Provincial Hospital of Traditional Chinese Medicine)

研究负责人所在单位:

南京中医药大学附属医院(江苏省中医院)

Affiliation of the Leader:

Nanjing University of Traditional Chinese Medicine Affiliated Hospital (Jiangsu Provincial Hospital of Traditional Chinese Medicine)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024NL-127-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南京中医药大学附属医院(江苏省中医院)伦理委员会

Name of the ethic committee:

Ethics Committee of Nanjing University of Traditional Chinese Medicine Affiliated Hospital (Jiangsu Provincial Hospital of Traditional Chinese Medicine)

伦理委员会批准日期:

Date of approved by ethic committee:

2024-07-16 00:00:00

伦理委员会联系人:

王卯

Contact Name of the ethic committee:

Mao Wang

伦理委员会联系地址:

南京中医药大学附属医院(江苏省中医院)伦理委员会

Contact Address of the ethic committee:

Ethics Committee of Nanjing University of Traditional Chinese Medicine Affiliated Hospital (Jiangsu Provincial Hospital of Traditional Chinese Medicine)

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 0656 0515

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南京中医药大学附属医院(江苏省中医院)

Primary sponsor:

Nanjing University of Traditional Chinese Medicine Affiliated Hospital (Jiangsu Provincial Hospital of Traditional Chinese Medicine)

研究实施负责(组长)单位地址:

江苏省南京市秦淮区汉中路155号

Primary sponsor's address:

155 Hanzhong Road, Qinhuai District, Nanjing, Jiangsu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

南京市

Country:

CHINA

Province:

Jiangsu Province

City:

NanJing

单位(医院):

南京中医药大学附属医院(江苏省中医院)

具体地址:

秦淮区汉中路155号

Institution
hospital:

Nanjing University of Traditional Chinese Medicine Affiliated Hospital (Jiangsu Provincial Hospital of Traditional Chinese Medicine)

Address:

155 Hanzhong Road, Qinhuai District, Nanjing, Jiangsu

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

研究疾病:

肛瘘  

Target disease:

Anal fistula

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

单臂 

Study design:

Single arm 

研究目的:

评价侧移黏膜瓣术治疗复杂性肛瘘的临床疗效  

Objectives of Study:

Evaluate the clinical efficacy of lateral mucosal flap surgery in the treatment of complex anal fistula

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.纳入标准以外的其它类型肛瘘或合并高位括约肌间病灶; 2.肛瘘合并结直肠良恶性肿瘤、直肠息肉、炎症性肠病活动期或结核病等疾 病者; 3.年龄在18周岁以下或70周岁以上者,或依从性差,或为妊娠期、哺乳期的妇女; 4.合并有心血管、肝肾疾病或严重造血异常疾病、精神病的患者; 5.合并糖尿病、免疫系统异常的患者; 6.疤痕体质的患者。

Exclusion criteria:

1. Other types of anal fistula or combined high intersphincteric lesions beyond the inclusion criteria; 2. Anal fistula with colorectal benign and malignant tumors, rectal polyps, active inflammatory bowel disease or tuberculosis and other diseases; 3. Women who are under 18 years old or over 70 years old, have poor compliance, or are pregnant or breastfeeding; 4. Patients with cardiovascular, liver and kidney diseases, severe hematopoietic disorders, or mental illnesses; 5. Patients with diabetes and abnormal immune system; 6. Patients with scar constitution.

研究实施时间:

Study execute time:

From 2024-07-01 00:00:00 To 2025-07-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-07-31 00:00:00 To 2025-07-01 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

100

Group:

Test group

Sample size:

干预措施:

侧移黏膜瓣术

干预措施代码:

A

Intervention:

Lateral mucosal flap surgery

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏省 

市(区县):

南京市 

Country:

CHINA

Province:

Jiangsu

City:

Nanjing

单位(医院):

南京中医药大学附属医院 

单位级别:

三甲 

Institution
hospital:

Nanjing University of Traditional Chinese Medicine Affiliated Hospital (Jiangsu Provincial Hospital of Traditional Chinese Medicine)

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

瘘管临床愈合率

指标类型:

主要指标

Outcome:

Simple Endoscopic Score (SES-CD)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

瘘管应答率

指标类型:

次要指标

Outcome:

Fistula response rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

肛周瘘管

组织:

肛周瘘管

Sample Name:

Perianal fistula

Tissue:

Perianal fistula

人体标本去向

使用后销毁  

说明

2年

Fate of sample:

Destruction after use  

Note:

2

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2026年10月 向主研人申请

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Apply to the principal investigator in October 2026

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表,电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record form, electronic collection and management system

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-07-24 18:37:14